Genomic Testing

FOUNDATIONONE®HEME

Test for hematologic malignancies and sarcomas including but not limited to: Leukemias, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Lymphomas, Multiple Myeloma, Ewing Sarcoma, and Leiomyosarcoma
  • Cancer Type
    Hematologic Malignancies, Sarcomas
  • Sample Type
    FFPE, Peripheral Whole Blood, Bone Marrow Aspirate
  • Results Expected
    3 weeks*

What is FoundationOne Heme?

FoundationOne Heme is a comprehensive genomic profiling test for hematologic malignancies and sarcomas. The test is designed to provide physicians with clinically actionable information to help with diagnostic subclassification, prognosis assessment, and targeted therapeutic selection. Test results provide information about clinically relevant alterations, potential targeted therapies, available clinical trials, and quantitative biomarkers that may support immunotherapy clinical trial enrollment.

FoundationOne Heme is validated to detect the four main classes of genomic alterations in more than 400 cancer-related genes. In addition to DNA sequencing, FoundationOne Heme employs RNA sequencing across more than 250 genes to capture a broad range of gene fusions, common drivers of hematologic malignancies, and sarcomas.

Overview

FoundationOne Heme

  • >400

    genes interrogated

  • >30

    select introns profiled

  • >250

    RNA-sequenced genes

  1. A single test that detects the four main classes of genomic alterations for hematologic cancers and sarcomas
  2. Uses both DNA and RNA sequencing for sensitive detection of translocations and fusions
  3. Reports tumor mutational burden (TMB) and microsatellite instability (MSI), which may inform clinical decision making and clinical trial enrollment
Gene List →

Publications

FoundationOne Heme has been validated to detect all four classes of genomic alterations.

Validation Study in Blood

Published Clinical Study

Patient-derived xenotransplants (PDX) can recapitulate the genetic driver landscape of acute leukemias

These data emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.

View the Published Paper

Published Clinical Study

Antitumor response of VEGFR2- and VEGFR3-amplified angiosarcoma to pazopanib

This exceptional response to pazopanib treatment suggests that a subset of patients with angiosarcoma with genomic alterations in vascular signaling genes may respond well to pazopanib.

View the Published Paper

Explore a selection of the 300+ articles we've published since our founding.

View all reports and validation

Order FoundationOne Heme

We provide physicians with several options for ordering FoundationOne Heme for patients including online, fax, and e-mail. Physicians must first complete a test requisition form to start the process and can expect results within 3 weeks from the time a specimen is received.

A doctor looking at the camera

Providers

FoundationOne Heme can be ordered online, by fax, or by phone. Please review and complete the provider resources before ordering.

Order a Test

Provider Resources

Patients

FoundationOne Heme is ordered by your healthcare provider and we offer financial assistance for those who qualify. Download our form or apply online and speak with your healthcare provider today.

Apply Now

Patient Resources

Questions? We’re here to help.

Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours.

Contact Us

We have even more to offer.

Learn more about our other tests, FoundationOne®Liquid, FoundationOne®CDx, or explore insights and trials or partnerships.

* Typical turnaround time from receipt of specimen is three weeks